The war against Alzheimer’s disease has been a brutal, losing fight. Those stricken with the disease, their loved ones, and their doctors are on the front lines every day, but the battles researchers and drug companies fight behind the scenes in labs also have led to virtually no victories.
Accera, an early stage drug company based in Broomfield, CO, thinks it might have a winning strategy with its new drug candidate, AC-1204. Accera is moving beyond its origins as a “medical food” company and is remaking itself into a pharmaceutical company. It wants to use the expertise it developed creating a special supplement for Alzheimer’s patients to create what it says will be a first-of-its-kind drug that attacks Alzheimer’s in a new way.